bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prediagnostic Image Data, Artificial Intelligence, and Pancreatic Cancer
Authors: Young Matthew R. , Abrams Natalie , Ghosh Sharmistha , Rinaudo Jo Ann S. , Marquez Guillermo , Srivastava Sudhir 
Published: July 2020

Abstract
Pancreatic cancer continues to be one of the deadliest malignancies and is the third leading cause of cancer-related mortality in the United States. Based on several models, it is projected to become the second leading cause of cancer-related deaths by 2030. Although the overall survival rate for patients diagnosed with pancreatic cancer is less than 10%, survival rates are increasing in those whose cancers are detected at an early stage, when intervention is possible. There are, however, no reliable biomarkers or imaging technology that can detect early-stage pancreatic cancer or accurately identify precursors that are likely to progress to malignancy. The Alliance of Pancreatic Cancer Consortia, a virtual consortium of researchers, clinicians, and advocacies focused on early diagnosis of pancreatic cancer, was formed in 2016 to provide a platform and resources to discover and validate biomarkers and imaging methods for early detection. The focus of discussion at the most recent alliance meeting was on imaging methods and the use of artificial intelligence for early detection of pancreatic cancer.
A Quality Initiative for Reducing Postoperative Hypothermia for Neonatal Intensive Care Unit Surgical Patients
Authors: Cronin Jessica A. , Soghier Lamia , Ryan Kara , Shen Christine , Bhattarai Sopnil , Rana Sohel , Shah Rahul , Heitmiller Eugenie 
Published: July 2020

Introduction:
The association between hypothermia in the neonatal intensive care unit (NICU) patients and morbidity and mortality is well described. Neonates are at higher risk of perioperative hypothermia when compared to older children. Previous studies showed that quality improvement tools reduced postoperative hypothermia in NICU patients, but none showed sustained improvement at incidence rates of <10%. As a single institution, we aimed to reduce the percentage of postoperative temperatures < 36°C in NICU patients from 10% to 6% over 6 months and sustain for 6 months.

Methods:
An interdisciplinary team created a key driver diagram and implemented interventions, including monthly reporting of postoperative hypothermia incidence to the anesthesiologists, individual feedback sessions with the anesthesiologists, use of a perioperative checklist, and continuous axillary temperature monitoring of the infant throughout the perioperative period. Data were collected retrospectively using a chart review of electronic medical records. The primary outcome was the percentage of hypothermic patients (T < 36°C) based on the first postoperative temperature taken in the NICU. We tracked this measure using a statistical control chart and evaluated it using Plan-Do-Study-Act cycles.

Results:
From February 1, 2016 to May 30, 2018, data were collected for 554 patients (pre-intervention: 242 and post-intervention: 312). The percentage of surgical patients who returned to the NICU hypothermic decreased from 9.7% to 2.5% (P < 0.002)—a change sustained for greater than 12 months.

Conclusions:
Quality improvement tools are useful in reducing postoperative hypothermia in NICU surgical patients and in maintaining these results.
A Positive Psychology–Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity in Type 2 Diabetes: The BEHOLD-8 Controlled Clinical Trial
Authors: Huffman Jeff C. , Golden Julia , Massey Christina N. , Feig Emily H. , Chung Wei-Jean , Millstein Rachel A. , Brown Lydia , Gianangelo Taylor , Healy Brian C. , Wexler Deborah J. , Park Elyse R. , Celano Christopher M. 
Published: July 2020

ABSTRACT

Objective
Physical activity is associated with superior health outcomes in patients with type 2 diabetes (T2D), but most T2D patients do not follow physical activity recommendations. The objective of this study was to assess the feasibility and impact of a novel combined positive psychology–motivational interviewing (PP-MI) intervention to promote physical activity in T2D.

Methods
This controlled clinical trial compared an 8-week, phone-delivered PP-MI intervention to an attention-matched MI-enhanced behavioral counseling condition among 60 participants with T2D and suboptimal moderate to vigorous physical activity (MVPA; <150 min/wk). The primary study outcome was feasibility (proportion of sessions completed) and acceptability (0–10 ease and utility ratings of each session). Secondary outcomes were between-group differences in changes in positive affect (main psychological outcome) and accelerometer-measured physical activity (MVPA and steps per day), using mixed-effects regression models, at 8 and 16 weeks.

Results
Ninety-two percent of PP-MI sessions were completed, and mean participant ratings of ease/utility were 8.5 to 8.8/10, surpassing a priori benchmarks for feasibility and acceptability. PP-MI participants had small-medium effect size (ES) difference improvements in positive affect compared with MI (8 weeks: estimated mean difference [EMD] = 3.07 [SE = 1.41], p = .029, ES = 0.44; 16 weeks: EMD = 2.92 [SE = 1.73], p = .092, ES = 0.42). PP-MI participants also had greater improvements in MVPA (8 weeks: EMD = 13.05 min/d [SE = 5.00], p = .009, ES = 1.24; 16 weeks: EMD = 7.96 [SE = 4.53], p = .079, ES = 0.75), with similar improvements in steps per day.

Conclusions
The PP-MI intervention was feasible and well accepted. Next-step efficacy studies can more rigorously explore the intervention’s effects on physical activity and clinical outcomes.

Trial Registration: ClinicalTrials.gov Registration No. NCT03150199.
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa
Authors: Inzaule Seth C. , Bertagnolio Silvia , Kityo Cissy M. , Siwale Margaret , Akanmu Sulaimon , Wellington Maureen , de Jager Marleen , Ive Prudence , Mandaliya Kishor , Stevens Wendy , Boender Tamara S. , Ondoa Pascale , Sigaloff Kim C.E. , Rinke de Wit Tobias F. , Hamers Raph L. 
Published: July 2020

Introduction:
To achieve viral suppression among more than 90% of people on antiretroviral therapy (ART), improved understanding is warranted of the modifiable causes of HIV viremic episodes. We assessed the relative contributions of drug-resistance, nonadherence and low-level viremia (LLV) (viral load 50–999 cps/ml) on viremic episodes in sub-Saharan Africa.

Methods:
In a multicountry adult cohort initiating nonnucleoside reverse transcriptase inhibitor-based first-line ART, viremic episodes (viral load ≥1000 cps/ml) were classified as first, viral nonsuppression at 12 months; second, virological rebound at 24 months (after initial viral suppression at 12 months); third, failure to achieve viral resuppression at 24 months (after viremic episode at 12 months). We used adjusted odds ratios from multivariable logistic regression to estimate attributable fractions for each risk factor.

Results:
Of 2737 cohort participants, 1935 had data on pretreatment drug resistance (PDR) and at least 1 viral load outcome. Viral nonsuppression episodes [173/1935 (8.9%)] were attributable to nonadherence in 30% (35% in men vs. 24% in women) and to PDR to nonnucleoside reverse transcriptase inhibitors in 10% (15% in women vs. 6% in men). Notably, at contemporary PDR prevalences of 10–25%, PDR would explain 13–30% of viral nonsuppression. Virological rebound episodes [96/1515 (6.3%)] were mostly attributable to LLV (29%) and nonadherence (14%), and only rarely to PDR (1.1%). Failures to achieve viral resuppression [66/81 (81.5%)] were mostly attributable to the presence of acquired drug resistance (34%) and only rarely to nonadherence (2.4%).

Conclusion:
Effective adherence interventions could substantially reduce viral nonsuppression (especially in men) and virological rebound (especially during LLV), but would have limited effect on improving viral resuppression. Alternative ART regimens could circumvent PDR and acquired resistance.
Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial
Authors: Tukei Betty B. , Fatti Geoffrey , Tiam Appolinaire , Ngorima-Mabhena Nicoletta , Tukei Vincent J. , Tshabalala Itumeleng , Sejana Veronica M. , Muzenda Trish , Mokoroane Lincoln M. , Sehlabo Lebelang , Maotoe Thapelo , Mirembe Justine K. , Membe Ian , Akpan Francis , Maile Khotso , Faturiyele Iyiola , Xulu Thembi , Minior Thomas , Sanne Ian , Chasela Charles ,   for EQUIP Health
Published: July 2020

Background:
Lesotho adopted the test-and-treat approach for HIV treatment in June 2016, which increased antiretroviral treatment (ART) clinic volume. We evaluated community-based vs. facility-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho.

Methods:
Thirty facilities were randomized to 3 arms, facility 3-monthly ART (3MF) (control), community ART groups (3MC), and 6-monthly community distribution points (6MCD). We estimated risk differences (RDs) between arms using population-averaged generalized estimating equations, controlling for baseline imbalances and specifying for clustering. The primary outcome was retention in ART care by intention-to-treat and virologic suppression as a secondary outcome (ClinicalTrials.gov: NCT03438370).

Results:
A total of 5,336 participants were enrolled, with 1898, 1558, and 1880 in 3MF, 3MC, and 6MCD, respectively. Retention in ART care was not different across arms and achieved the prespecified noninferiority limit (−3.25%) between 3MC vs. 3MF (control); 6MCD vs. 3MF; and 6MCD vs. 3MC, adjusted RD = −0.1% [95% confidence interval (CI): −1.6% to 1.5%], adjusted RD = −1.3% (95% CI: −3.0% to 0.5%), and adjusted RD = −1.2% (95% CI: −2.9% to 0.5%), respectively. After 12 months, 98.6% (n = 1503), 98.1% (n = 1126), and 98.3% (n = 1285) were virally load (VL) suppressed in 3MF, 3MC, and 6MCD, respectively. There were no differences in VL between 3MC vs. control and 6MCD vs. control, risk ratio (RR) = 1.00 (95% CI: 0.98 to 1.01) and RR = 1.00 (95% CI: 0.98 to 1.01), respectively.

Conclusions:
There were no differences in retention and VL suppression for stable HIV-infected participants receiving multimonth dispensing of ART within community-based differentiated models when compared with the facility-based standard-of-care model.
Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial
Authors: McCammon Kurt , Gousse Angelo , Kohan Alfred , Glazier David , Gruenenfelder Jennifer , Bai Zhanying , Patel Anand , Hale Douglass 
Published: July 2020

Objectives
This randomized, multicenter, placebo-controlled, phase IV study assessed the efficacy and tolerability of onabotulinumtoxinA in patients with overactive bladder.

Methods
Patients were randomized 1:1 to onabotulinumtoxinA 100 U or placebo. Assessments over 12 weeks included: change from baseline in urinary incontinence (UI) episodes/day; proportions of patients who achieved 100% and 50% or greater reductions in UI episodes/day; proportion of patients using no incontinence pads in the previous 24 hours; and changes from baseline in micturition frequency, nocturia, urgency UI, Incontinence-Quality of Life, King’s Health Questionnaire, International Consultation on Incontinence Questionnaire—UI Short Form scores and time to request retreatment.

Results
Significant reductions in UI episodes/day were seen with onabotulinumtoxinA versus placebo within week 1 posttreatment (−2.9 vs −2.0, P = 0.005) through week 12 (coprimary endpoint: −3.5 vs −1.6, P < 0.001). Significantly more onabotulinumtoxinA-treated patients achieved 100% (coprimary endpoint) and 50% or greater reductions in UI episodes/day. Decreases in other urinary symptoms were also seen within 1 week with onabotulinumtoxinA that continued through at least week 12. More onabotulinumtoxinA-treated versus placebo-treated patients required no incontinence pads at weeks 1 to 12, and greater improvements in quality of life measurements were seen. Time to request retreatment was significantly longer with onabotulinumtoxinA versus placebo (30.0 weeks vs 13.1 weeks; P < 0.001). No unexpected safety signals were observed. Urinary tract infection was the most commonly observed adverse event.

Conclusions
Urinary symptom and quality of life improvements were observed with onabotulinumtoxinA within 1 week of treatment and were sustained for at least 12 weeks.
Effect of Lomerizine Hydrochloride on Preventing Strokes in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
Authors: Watanabe-Hosomi Akiko , Mizuta Ikuko , Koizumi Takashi , Yokota Isao , Mukai Mao , Hamano Ai , Kondo Masaki , Fujii Akihiro , Matsui Masaru , Matsuo Koushun , Ito Keita , Teramukai Satoshi , Yamada Kei , Nakagawa Masanori , Mizuno Toshiki 
Published: July 2020

Background
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an orphan disease clinically characterized by migraine, recurrent strokes, and dementia. Currently, there are no disease-modifying therapies, and it is difficult to prevent cerebral ischemic events in CADASIL patients by conventional antithrombotic medication. We hypothesized that an antimigraine agent, lomerizine hydrochloride, may prevent strokes in CADASIL patients, based on its effect on increasing cerebral blood flow.

Subjects and Methods
This was an open-labeled clinical trial in which 30 adult CADASIL patients received lomerizine at 10 mg/d. Numbers of symptomatic strokes during the 2 years after the start of lomerizine administration were compared with those in the 2 years before its initiation. The effect of lomerizine on preventing strokes was evaluated based on the incidence rate ratio (IR) calculated with the Mantel-Haenszel method.

Results
When including all 30 patients (analysis 1), the IR was less than 1 (0.46; 95% confidence interval [CI], 0.19–1.12) but did not reach significance. To evaluate the effect of lomerizine on secondary prevention, subgroups of 15 patients with stroke episodes occurring any time before lomerizine administration (analysis 2) and 10 patients with stroke episodes during the 2 years before lomerizine administration (analysis 3) were analyzed. The IR values were 0.33 (95% CI, 0.12–0.94) in analysis 2 and 0.17 (95% CI, 0.04–0.67) in analysis 3.

Conclusions
Our results suggest the effect of lomerizine on preventing secondary stroke in CADASIL patients.
In silico prediction and in vitro assessment of microbial substrate utilisation: a focus on newly identified health promoting gut bacteria
Authors: Lordan Cathy , Walsh Aaron M. , Paul Ross R. , Cotter Paul D. 
Published: July 2020

The contribution of the gut microbiota to health and disease is becoming ever more apparent in the last number of years, due to developments in DNA sequencing technology and more well-defined cultivation techniques. This has resulted in the identification of health-promoting bacteria. Until recently, prebiotics, non-digestible food substrates which are selectively utilised by beneficial bacteria, were employed with a view to increasing the growth of well-established health promoting bacteria, namely Lactobacillus and Bifidobacterium. However, other beneficial bacteria recently revealed may also be targeted to enhance their growth as they establish themselves as the next generation of health-promoting microbes. These include anaerobes such as Akkermansia muciniphila, Faecalibacterium prausnitzii and Eubacterium rectale. Identification of growth substrates/bioactives through the analysis of genome sequence data can aid in elucidating which substrates may best enhance the growth of these microbes which are often difficult to grow.
The phenotypic microbial trait analyser, Traitar, can predict 67 phenotypes based on the genome sequence inputted. Some of these traits include substrates that could potentially be utilised by the bacteria. Another tool, CarveMe, which has been created with the aim of making metabolic modelling more user-friendly, was also used with the same genomes. A select number of substrates identified in both tools have been chosen to be evaluated in vitro in order to establish the accuracy of these predictive tools as well as giving an indication as to how these beneficial microbes can be modulated through dietary components.
Intelligent wound dressing for diagnostic & therapeutic applications - critical to wound infection
Authors: Mahmood Zahid , Salisbury Anne-Marie , Chen Rui , Rimmer Stephen , Percival Steven 
Published: July 2020

A medical device comprising of biomaterials responsive to biochemical stimuli: channel for indicating the infective states of wounds and ensuring delivery of smart antimicrobial and antibiofilm agents to promote tissue regeneration and healing.
The importance of providing diagnostic wound dressings that can inform healthcare professionals on the state of infection within wounds but also provide some of the treatment required in response to at risk or infected wounds is of key interest. The aim is to investigate an innovative proof of concept diagnostic and detection system, an intelligent hydrogel wound dressing that responds to specific biochemical stimuli in wounds (MMPs and pH) enabling the selective and triggered release of antibiofilm and antimicrobial agents (‘Detect and Treat’)to the trauma site. The dressing is made of a sterile alginate core material covered in a biocompatible dry or hydrated peptide-polymer-complex film and may include a fluorescent dye which upon release during the wound healing process indicates when a change in dressing is necessary. Efficacy studies of the hydrogel dressing were performed within a drip-flow bioreactor in which regression of Pseudomonas aeruginosa biofilm was observed. A 5-log reduction in biofilm was observed in comparison to an untreated control biofilm. The hydrogel dressing indicated a clear response when in contact with biofilms produced only by pathogenic strains of bacteria when analysed. This further confirmed the adequate release and function of the antimicrobial and antibiofilm agents within the peptide-polymer-complex formulation of the hydrogel wound dressing.
Engineered ureolytic Bacillus subtilis and its future in Microbial Induced Calcium Carbonate Precipitation (MICCP)
Authors: Wright Jennifer , Moreland Polly , Wipat Anil , Zhang Meng , Dade-Robertson Martyn 
Published: July 2020

As the global population grows there is an urgent need for increased, yet sustainable civil infrastructure. The ability to harness biological processes in order to improve ground stability; as well as creating construction materials without adding to climate damage is necessary. In almost every environment on earth, microorganisms and microbially mediated mineralisation (biomineralisation) processes are active. It is well documented that microbes present in soil can induce the precipitation of calcium carbonate (CaCO3) in both the laboratory and the natural setting through microbial induced calcium carbonate precipitation (MICCP). MICCP utilises microorganisms as a result of their active metabolism, to precipitate CaCO3, strengthening the surrounding matrix. MICCP is used in a variety of different applications such as carbon sequestration, environmental remediation and improving construction materials.
The enzyme urease catalyzes the hydrolysis of urea to ammonia and CO2, and is acknowledged to be instrumental in MICCP. Bacillus subtilis is a model, gram positive, spore-forming soil bacterium that produces a functionally active urease, but with low efficiency, and the activation is not completely understood. Sporosarcina pasteurii is one of the most commonly used MICCP microbes as its urease operon has been well studied and the bacterium has proven to produce ecologically stable bioconstruction materials. The ability to clone the urease operon of S. pasteurii into the model B. subtilis would create an engineered ureolytic organism whose urease activity could be controlled. This control would enable the CaCO3 morphology and material properties to be tailored and would create a truly responsive biomaterial.
Characterisation of the antimicrobial mode of action of gallium maltolate
Authors: Piatek Magdalena , Griffith Darren , Kavanagh Kevin 
Published: July 2020

To human health worldwide. Existing treatments are becoming inefficacious and therefore there is an urgent need for the development of treatments with alternative modes of action. The use of gallium as an antimicrobial agent has been of interest due to its unconventional mode of action involving the inhibition of iron acquisition and metabolism. The structural similarity and inability to reduce from a trivalent to divalent form under normal physiological conditions allows gallium to act as an iron mimetic and inhibit many iron-dependent biological pathways, respectively.
The antimicrobial potential of gallium maltolate (GaM), Ga(III) coordination complex of maltol, was investigated on the opportunistic pathogen Pseudomonas aeruginosa. In vitro and in vivo analyses using Galleria mellonella (greater wax moth) larvae demonstrated the potent bacteriostatic and non-toxic effect of the complex. Subsequent analysis of GaM treated P. aeruginosa via label-free quantitative proteomics provided an insight into the intrinsic mechanisms of action of GaM. Increased expression of iron-storage protein Bacterioferritin B, the HemO component of iron-sulfur clusters and several stress response proteins (Chaperone Proteins ClpB, HtpG and DnaJ) indicate cell stress in response to inhibited iron uptake. Decreased expression of LasA Protease and LasB Elastase quorum-sensing proteins and flagellar motility proteins FlgM and FlgG further demonstrate the growth inhibitory effect of GaM. These findings provide a basis for a better understanding of the mode of action of GaM, a requirement for the improvement of synthesis and efficacy of the treatment.
‘Seq & Destroy’: the full genome sequencing of archived wild type and vaccine rinderpest virus isolates prior to their destruction
Authors: King Simon , Rajko-Nenow Paulina , Ropiak Honorata , Ribeca Paolo , Batten Carrie , D. Baron Michael 
Published: July 2020

Rinderpest, a once much feared livestock disease, was declared eradicated in 2011, however virus-containing material is still held in laboratories worldwide. Prior to the destruction of our institute’s stocks, we determined the full genome sequence of the distinct samples of rinderpest virus (RPV) in our repository. This data would decipher the historical epidemiology of RPV and allow for recovery of the virus should the need arise.
For each sample (n=123), sequencing libraries were prepared using either transposon-based fragmentation of cDNA (Nextera XT DNA Library Prep kit) or single primer isothermal amplification (Trio RNA-Seq kit) and sequenced on the Illumina MiSeq. Regions of low or no coverage were re-sequenced using a Sanger sequencing approach.
Examination of the sequences of RPV isolates has shown that the African isolates form a single disparate clade, rather than two separate clades as was previously believed. We have also identified two groups of goat-passaged viruses which have acquired an extra 6 bases in the long untranslated region between the matrix and fusion protein coding sequences, and a group of African isolates where translation of the fusion protein begins from a non-standard start codon (AUA). In addition, the viruses that were force-passaged through alternate hosts such as rabbits or goats, appear to diverge from the clades that represent viruses which were maintained in the wild.
Our unique set of sequence data will be invaluable for forensic epidemiology investigations in the event of an unforeseen outbreak and aid in the understanding of the evolution of related morbilliviruses.